Befungin (Solution, Concentrate) Instructions for Use
ATC Code
A13A (General tonic preparations)
Active Substance
Inonotus obliguus
Inonotus obliguus (SP State Pharmacopoeia)
Clinical-Pharmacological Group
Herbal immunostimulant drug
Pharmacotherapeutic Group
General tonic agent
Pharmacological Action
A preparation from the phytopathogenic fungus Inonotus obliquus (birch polypore), which develops in the form of growths on birch trunks.
The main active substances are pigments forming a chromogenic polyphenolcarboxylic complex (20%) in combination with polysaccharides (6-8%), agaricic and humin-like chagic acids.
The tonic effect on the central nervous system and immunomodulating properties provide increased body resistance to hypoxia and other adverse effects.
The presence of copper, manganese, and cobalt provides a stimulating effect on hematopoiesis, especially on leukopoiesis.
Birch polypore preparations have a gastroprotective action and normalize the functions of the digestive glands.
Increased functional activity of the immune system, especially the function of natural killer cells, apparently determines the antitumor properties of the birch polypore.
Indications
Gastrointestinal dyskinesia of the hypotonic type, gastric and duodenal ulcer, chronic gastritis; asthenic conditions, cachexia, postoperative period, long-term immunosuppressive therapy.
ICD codes
| ICD-10 code | Indication |
| F48.0 | Neurasthenia |
| K25 | Gastric ulcer |
| K26 | Duodenal ulcer |
| K29 | Gastritis and duodenitis |
| K59.8 | Other specified functional intestinal disorders |
| R53 | Malaise and fatigue |
| R64 | Cachexia |
| Y43.4 | Immunosuppressive agents |
| Z54.0 | Convalescence following surgery |
| ICD-11 code | Indication |
| 6A8Z | Affective disorders, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA60.Z | Gastric ulcer, unspecified |
| DA63.Z | Duodenal ulcer, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DB32.3 | Acquired hypoganglionosis of the colon |
| DB32.Z | Colonic motility disorders, unspecified |
| DD90.2 | Functional heartburn |
| DD91.Y | Other specified irritable bowel syndrome or functional bowel disorders |
| DD93.Y | Other specified functional gastrointestinal disorders in infants, toddlers and school-age children |
| MG20.Z | Cachexia, unspecified |
| MG22 | Asthenia |
| MG25 | Malaise |
| PL00 | Drugs, medicaments or biological substances causing injury or harm in therapeutic use |
| QB7Y | Other specified convalescence |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Concentrate
Orally, as a solution.
To prepare the solution, shake the contents of the bottle, dilute 3 teaspoons of the preparation in 150 ml of warm boiled water.
Take 1 tablespoon 3 times a day 30 minutes before meals.
The treatment course is 3-5 months.
If necessary, the course is repeated after a 7-10-day break.
Solution
Take orally.
The treatment course is 1-5 months.
If necessary, the treatment course is repeated after a 7-10-day break.
Adverse Reactions
Possible allergic reactions.
Contraindications
Hypersensitivity to birch polypore preparations; pregnancy, breastfeeding period; children under 18 years of age.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and breastfeeding.
Pediatric Use
Contraindicated for use in children and adolescents under 18 years of age.
Special Precautions
When treating with birch polypore preparations, a milk-plant diet with the exclusion of canned food, spicy seasonings, and animal fats is recommended.
The use of penicillin and intravenous administration of dextrose is contraindicated.
It can be used in complex therapy for tumor diseases to improve hematopoiesis and digestion processes.
Storage Conditions
Store at 8°C (46°F) to 15°C (59°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Concentrate for solution for oral administration 1 kg/1 l: fl.
Marketing Authorization Holder
Aspen Pharma, Pty. Ltd. (India)
Manufactured By
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
 |
Befungin | Concentrate for solution for oral administration 1 kg/1 l: fl. |
Dosage Form, Packaging, and Composition
| Concentrate for solution for oral administration | 1 l |
| Inonotus obliguus | 1 kg |
Excipients : cobalt chloride/cobalt sulfate.
Bottles (1) – cardboard packs.
Concentrate for solution for oral administration 1 kg/1 l: fl. 50 ml or 100 ml
Marketing Authorization Holder
Vifitech, CJSC (Russia)
Dosage Form
|
Befungin | Concentrate for solution for oral administration 1 kg/1 l: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
| Concentrate for solution for oral administration | 1 l |
| Inonotus obliguus | 1 kg |
Excipients : cobalt chloride.
100 ml – bottles (1) – cardboard packs.
100 ml – dark glass bottles (1) – cardboard packs.
50 ml – dark glass bottles (1) – cardboard packs.
Oral solution 1 kg/1 l: fl. 100 ml
Marketing Authorization Holder
Murom Instrument-Making Plant, FSUE (Russia)
Dosage Form
|
Befungin | Oral solution 1 kg/1 l: fl. 100 ml |
Dosage Form, Packaging, and Composition
| Oral solution | 1 l |
| Inonotus obliguus | 1 kg |
Excipients : cobalt chloride.
100 ml – dark glass bottles (1) – cardboard packs.
Oral solution 1 kg/1 l: fl. 50 ml or 100 ml
Marketing Authorization Holder
Tatkhimpharmpreparaty, JSC (Russia)
Dosage Form
|
Befungin | Oral solution 1 kg/1 l: fl. 50 ml or 100 ml |
Dosage Form, Packaging, and Composition
| Oral solution | 1 l |
| Inonotus obliguus | 1 kg |
Excipients : cobalt chloride.
50 ml – dark glass bottles (1) – cardboard packs.
100 ml – dark glass bottles (1) – cardboard packs.
100 ml – bottles (1) – cardboard packs.
Concentrate for solution for oral administration 1 kg/1 l: fl. 100 ml
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
|
Befungin | Concentrate for solution for oral administration 1 kg/1 l: fl. 100 ml |
Dosage Form, Packaging, and Composition
Concentrate for solution for oral administration in the form of a dark brown liquid; precipitation is allowed during storage.
| 1 l | |
| Birch polypore (chaga) | 1 kg |
| Cobalt chloride hexahydrate | 1.75 g |
Excipients : ethanol 95% 100 g, purified water as needed to obtain 1000 ml of the preparation.
40 ml – orange glass bottles (1) – cardboard packs.
50 ml – orange glass bottles (1) – cardboard packs.
100 ml – orange glass bottles (1) – cardboard packs.
Oral solution 1 kg/1 l: fl. 100 ml
Marketing Authorization Holder
Yaroslavl Pharmaceutical Factory, CJSC (Russia)
Dosage Form
|
Befungin | Oral solution 1 kg/1 l: fl. 100 ml |
Dosage Form, Packaging, and Composition
| Oral solution | 1 l |
| Inonotus obliguus | 1 kg |
Excipients : cobalt chloride.
100 ml – dark glass bottles (1) – paper packs.
![Befungin [Solution, Concentrate] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Befungin [Solution, Concentrate] 2")